The Brucella Melitensis M5-90 Phosphoglucomutase (PGM) Mutant is Attenuated and Confers Protection Against Wild-type Challenge in BALB/c Mice

Overview

Journal World J Microbiol Biotechnol

Publisher Springer

Specialties Biotechnology
Microbiology

Date 2016 Mar 2

PMID 26925620

Citations 11

Authors

Yu Zhang

Tiansen Li

Jing Zhang

Zhiqiang Li

Yan Zhang

Zhen Wang

Hanping Feng

Yuanzhi Wang

Chuangfu Chen

Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Brucellae are Gram-negative intracellular bacterial pathogens that infect humans and animals, bringing great economic burdens to developing countries. Live attenuated Brucella vaccines (strain M5-90 or others) are the most efficient means for prevention and control of animal brucellosis. However, these vaccines have several drawbacks, including residual virulence in animals, and difficulties in differentiating natural infection from vaccine immunization, which limit their application. A vaccine that can differentiate infection from immunization will have extensive applications. A Brucella melitensis (B. melitensis) strain M5-90 pgm mutant (M5-90Δpgm) was constructed to overcome these drawbacks. M5-90Δpgm showed significantly reduced survival in embryonic trophoblast cells and in mice, and induced high protective immunity in BALB/c mice. Moreover, M5-90Δpgm elicited an anti-Brucella-specific immunoglobulin G response and induced the secretion of gamma interferon (IFN-γ) and interleukin-2 (IL-2). In addition, M5-90Δpgm induced the secretion of IFN-γ in immunized sheep. Serum samples from sheep inoculated with M5-90Δpgm were negative by the Rose Bengal Plate Test (RBPT) and Standard Tube Agglutination Test (STAT). Furthermore, the PGM antigen allowed serological differentiation between infected and vaccinated animals. These results suggest that M5-90Δpgm is an ideal live attenuated vaccine candidate against B. melitensis 16 M and deserves further evaluation for vaccine development.

Citing Articles

Characterization of the and phosphoglucomutases (Pgm2s): a potential target for therapy.

Kottom T, Carmona E, Limper A Antimicrob Agents Chemother. 2024; 68(3):e0075623.

PMID: 38259086 PMC: 10916394. DOI: 10.1128/aac.00756-23.

Inflammatory Mechanism of Infection in Placental Trophoblast Cells.

Xiao Y, Li M, Guo X, Zeng H, Shuai X, Guo J Int J Mol Sci. 2022; 23(21).

PMID: 36362199 PMC: 9657658. DOI: 10.3390/ijms232113417.

Evaluation of Brucellosis Vaccines: A Comprehensive Review.

Heidary M, Dashtbin S, Ghanavati R, Mahdizade Ari M, Bostanghadiri N, Darbandi A Front Vet Sci. 2022; 9:925773.

PMID: 35923818 PMC: 9339783. DOI: 10.3389/fvets.2022.925773.

Glucose-1,6-Bisphosphate, a Key Metabolic Regulator, Is Synthesized by a Distinct Family of α-Phosphohexomutases Widely Distributed in Prokaryotes.

Neumann N, Friz S, Forchhammer K mBio. 2022; 13(4):e0146922.

PMID: 35856562 PMC: 9426568. DOI: 10.1128/mbio.01469-22.

-Induced Downregulation of lncRNA Gm28309 Triggers Macrophages Inflammatory Response Through the miR-3068-5p/NF-κB Pathway.

Deng X, Guo J, Sun Z, Liu L, Zhao T, Li J Front Immunol. 2021; 11:581517.

PMID: 33414782 PMC: 7784117. DOI: 10.3389/fimmu.2020.581517.

References

Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z . The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Vet Microbiol. 2011; 151(3-4):354-62. DOI: 10.1016/j.vetmic.2011.03.031. View

Pei J, Ficht T . Brucella abortus rough mutants are cytopathic for macrophages in culture. Infect Immun. 2003; 72(1):440-50. PMC: 343953. DOI: 10.1128/IAI.72.1.440-450.2004. View

Morgan W . The serological diagnosis of bovine brucellosis. Vet Rec. 1967; 80(21):612-20. DOI: 10.1136/vr.80.21.612. View

Schurig G, Sriranganathan N, Corbel M . Brucellosis vaccines: past, present and future. Vet Microbiol. 2002; 90(1-4):479-96. DOI: 10.1016/s0378-1135(02)00255-9. View

Moriyon I, Grillo M, Monreal D, Gonzalez D, Marin C, Lopez-Goni I . Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004; 35(1):1-38. DOI: 10.1051/vetres:2003037. View

Zhang J, Guo F, Chen C, Li Z, Zhang H, Wang Y . Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice. Microbiol Immunol. 2013; 57(7):502-10. DOI: 10.1111/1348-0421.12065. View

Murphy E, Sathiyaseelan J, Parent M, Zou B, Baldwin C . Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology. 2001; 103(4):511-8. PMC: 1783270. DOI: 10.1046/j.1365-2567.2001.01258.x. View

Li W, Hu X, Zhang X, Ge Y, Zhao S, Hu Y . Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice. Vaccine. 2011; 29(33):5526-33. DOI: 10.1016/j.vaccine.2011.05.030. View

Wu W, Weigand L, Mendez S . The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides. Can J Microbiol. 2009; 55(6):705-13. PMC: 2774832. DOI: 10.1139/w09-017. View

10.

Oliveira S, Splitter G . CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol. 1995; 25(9):2551-7. DOI: 10.1002/eji.1830250922. View

11.

Sathiyaseelan J, Goenka R, Parent M, Benson R, Murphy E, Fernandes D . Treatment of Brucella-susceptible mice with IL-12 increases primary and secondary immunity. Cell Immunol. 2006; 243(1):1-9. DOI: 10.1016/j.cellimm.2006.10.003. View

12.

Pugh Jr G, Zehr E, Meador V, Phillips M, McDonald T, DEYOE B . Immunologic, histopathologic, and bacteriologic responses of five strains of mice to Brucella abortus strain 2308. Am J Vet Res. 1989; 50(3):323-8. View

13.

Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G . Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun. 2005; 73(7):4198-204. PMC: 1168545. DOI: 10.1128/IAI.73.7.4198-4204.2005. View

14.

Hosseini Jazani N, Sohrabpour M, Mazloomi E, Shahabi S . A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol. 2010; 61(1):54-62. DOI: 10.1111/j.1574-695X.2010.00747.x. View

15.

Mosmann T, Sad S . The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996; 17(3):138-46. DOI: 10.1016/0167-5699(96)80606-2. View

16.

Golding B, Scott D, Scharf O, Huang L, Zaitseva M, Lapham C . Immunity and protection against Brucella abortus. Microbes Infect. 2001; 3(1):43-8. DOI: 10.1016/s1286-4579(00)01350-2. View

17.

Lindae A, Eberle R, Caruso I, Coronado M, de Moraes F, Azevedo V . Expression, purification and characterization of cold shock protein A of Corynebacterium pseudotuberculosis. Protein Expr Purif. 2015; 112:15-20. DOI: 10.1016/j.pep.2015.04.006. View

18.

Ugalde J, Comerci D, Leguizamon M, Ugalde R . Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infect Immun. 2003; 71(11):6264-9. PMC: 219583. DOI: 10.1128/IAI.71.11.6264-6269.2003. View

19.

Pugh Jr G, Tabatabai L, Phillips M, McDonald T . Establishment of dose-response relationships in BALB/c mice, using Brucella cell surface protein and lipopolysaccharide. Am J Vet Res. 1991; 52(2):261-8. View

20.

Hernandez-Castro R, Verdugo-Rodriguez A, Puente J, Suarez-Guemes F . The BMEI0216 gene of Brucella melitensis is required for internalization in HeLa cells. Microb Pathog. 2007; 44(1):28-33. DOI: 10.1016/j.micpath.2007.08.008. View